Access to care for multiple sclerosis in times of economic crisis in Greece – the hope ii study

International Journal of Health Policy and Management

Volumn 5, Issue 2, 2016, Pages 83-89

  Souliotis, Kyriakos ^a,b   Alexopoulou, Elena ^a,c   Papageorgiou, Manto ^a   Politi, Anastasia ^d   Litsa, Panagiota ^b   Contiades, Xenophon ^a  

^a UNIVERSITY OF PELOPONNESE   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Medicines Division   (Greece)

^d ATHENS UNIVERSITY OF ECONOMICS AND BUSINESS   (Greece)

Author keywords

Biologics; Greece; Multiple sclerosis (MS); Patient access; Pharmaceutical policy; Recession

Indexed keywords

BIOLOGICAL PRODUCT;

AMBULATORY CARE; DRUG COST; ECONOMIC RECESSION; ECONOMICS; FEMALE; GREECE; HUMAN; MALE; MULTIPLE SCLEROSIS; PHARMACY; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION;

BIOLOGICAL PRODUCTS; COMMUNITY PHARMACY SERVICES; DRUG COSTS; ECONOMIC RECESSION; FEMALE; GREECE; HUMANS; MALE; MULTIPLE SCLEROSIS; NATIONAL HEALTH PROGRAMS; OFFICE VISITS;

EID: 85002252517     PISSN: None     EISSN: 23225939     Source Type: Journal    
DOI: 10.15171/ijhpm.2015.173     Document Type: Article

References (15)

1. Maxwell RJ. Quality assessment in health. Br Med J (Clin Res Ed). 1984;288(6428):1470-1472. doi:10.1136/bmj.288.6428.1470
2. Põlluste K, Kalda R, Lember M. Satisfaction with the access to the health services of the people with chronic conditions in Estonia. Health Policy. 2007;82(1):51-61. doi:10.1016/j.healthpol.2006.08.004
3. Põlluste K, Kallikorm R, Meiesaar K, Lember M. Satisfaction with access to health services: the perspective of Estonian patients with rheumatoid arthritis. Sci World J. 2012;2012:257569. doi:10.1100/2012/257569
4. Multiple Sclerosis International Federation. Atlas of multiple sclerosis 2013. http://www.msif.org/includes/documents/cm_docs/2013/m/msif-atlas-of-ms-2013-report.pdf?f=1
5. Goldenberg MM. Multiple sclerosis review. P T. 2012;37(3):175-184.
6. Damal K, Stoker E, Foley JF. Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics. 2013;7:247-258. doi:10.2147/BTT.S53007
7. Kobelt G, Kasteng F. Access to innovative treatments in multiple sclerosis in Europe. Report prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA). http://www.comparatorreports.se/Access%20to%20MS%20treatments%20 -%20October%202009.pdf. Published October 2009.
8. Wilsdon T, Barron A, Mitchell- Heggs A, Ginoza S. Access to medicines for multiple sclerosis: challenges and opportunities. Report prepared for Biogen Idec. London; February 2014.
9. European Multiple Sclerosis Platform. MS Barometer 2013. http://www.emsp.org/wp-content/uploads/2015/06/130530-MS-Barometer-2013.pdf
10. National Organization for Medicines (EOF) website. http://www.eof.gr/web/guest/protocols
11. Souliotis K, Papageorgiou M, Politi A, Ioakeimidis D, Sidiropoulos P. Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: the unseen impact of the fiscal crisis--the Health Outcomes Patient Environment (HOPE) study. Rheumatol Int. 2014;34(1):25-33. doi:10.1007/s00296-013-2866-1
12. Laires PA, Exposto F, Mesquita R, Martins AP, Cunha-Miranda L, Fonseca JE. Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries. Eur J Health Econ. 2013;14(6):875-885. doi:10.1007/s10198-012-0432-5
13. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198-206. doi:10.1136/annrheumdis-2012-202603
14. Orlewska E, Ancuta I, Anic B, et al. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit. 2011;17(4):SR1-SR13. doi:10.12659/MSM.881697
15. Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? Ann Rheum Dis. 2014;73(11):2010-2021. doi:10.1136/annrheumdis-2013-203819